End-to-end drug and diagnostic development support for an immuno-oncology agent

Immuno-oncology drug development is inherently complex and requires special considerations across the entire spectrum, from preclinical to commercial support for the approved product. In this example, a prominent pharmaceutical company was developing an innovative new programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC). This company selected Labcorp for support at multiple junctures-from manufacturing to biomarker evaluation to market access-to enable a faster and more effective launch.